Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN-101 in C9ORF72 ALS/FTD
NCT04993755Phase 2Completed
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of censavudine in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), sponsored by Transposon Therapeutics, Inc.. Started Oct 2021; status: completed.
02
Drugs
censavudine
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04993755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993755.